High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country.
Bone Marrow Transplant
; 43(6): 481-9, 2009 Mar.
Article
em En
| MEDLINE
| ID: mdl-18978818
ABSTRACT
We analyzed the results of 108 patients (78 males and 30 females) with multiple myeloma who underwent autologous stem cell transplantation (ASCT). The median age of patients was 52 years (range, 26-68 years). High-dose melphalan (200 mg/m(2)) was used for conditioning. In all, 66 (61%) patients had evidence of chemo-sensitive disease before transplant. After ASCT 79.6% of patients responded complete response 36%, very good partial response 29.6%, and partial response 13.9%. Complete response rate was higher for patients with chemo-sensitive disease; 33 of 66 (50.0%) patients achieved complete response compared with 7 of 42 (14.3%) patients with progressive disease, P<0.01. Response rates to ASCT were significantly low for patients with Hb
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Condicionamento Pré-Transplante
/
Transplante de Células-Tronco
/
Mieloma Múltiplo
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article